Can nonliving nasal vaccines be made to work?

Expert Review of Vaccines

Volumn 1, Issue 2, 2002, Pages 227-232

  Haneberg, Bjørn ^a,b   Holst, Johan ^a  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Antibodies; Cellular immunity; Mucosal adjuvants; Mucosal vaccines; Protection

Indexed keywords

ADJUVANT; CHITOSAN; INFLUENZA VACCINE; MENINGOCOCCUS VACCINE; PERTUSSIS VACCINE;

ANTIBODY PRODUCTION; ANTIGEN ANTIBODY REACTION; CELL ADHESION; DOSE RESPONSE; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; HUMAN; IMMUNE SYSTEM; IMMUNIZATION; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; INFLUENZA VACCINATION; MENINGOCOCCOSIS; MUCOSAL IMMUNITY; NONHUMAN; NOSE MUCOSA; PARTICULATE MATTER; PRIORITY JOURNAL; REVIEW;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; AEROSOLS; ANIMALS; HUMANS; IMMUNOLOGIC MEMORY; MUCOUS MEMBRANE; PHARMACEUTICAL SOLUTIONS; VACCINES, INACTIVATED;

EID: 0038176268     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.1.2.227     Document Type: Review

References (47)

1. Brandtzaeg P, Farstad IN, Johansen F-E, Morton HC, Norderhaug IN, Yamanaka T. The B-cell system of human mucosa and exocrine glands. Immunol. Rev. 171, 45-87 (1999).
2. Rappuoli R, Pizza M, Douce G, Dougan G. Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins. Immunol. Today 20, 493-500 (1999).
3. Rask C, Fredriksson M, Lindblad M, Czerkinsky C, Holmgren J. Mucosal and systemic antibody responses after peroral or intranasal immunization: effects of conjugation to enterotoxin B subunits and/or of coadministration with free toxin as adjuvant. APMIS 108, 178-186 (2000).
4. Cong Y, Oliver AO, Elson CO. Effects of cholera toxin on macrophage production of co-stimulatory cytokines. Eur. J. Immunol. 31, 64-71 (2001).
5. Lycke N, Schön K. The B-cell targeted adjuvant, CTA1-DD, exhibits potent mucosal immunoenhancing activity despite pre-existing antitoxin immunity. Vaccine 19, 2542-2548 (2001).
6. Loon FPL van, Clemens JD, Chakraborty J et al. Field trial of inactivated oral cholera vaccines in Bangladesh: results from 5 years of follow-up. Vaccine 14, 162-166 (1996).
7. Neutra MR, Frey A, Kraehenbuhl J-P. Epithelial M cells: gateways for mucosal infection and immunization. Cell 86, 345-348 (1996).
8. Baumann E, Binder BR, Falk W, Huber EG, Kurz R, Rosanelli K. Development and clinical use of an oral heat-inactivated whole cell pertussis vaccine. Develop. Biol. Stand. 61, 511-516 (1985).
9. Jensen C. Active immunization against diphtheria by the combined subcutaneous and intranasal method. Proc. Royal Soc. Med. 30, 1117-1148 (1937).
10. Quilligan JJ Jr, Francis T Jr. Serological response to intranasal administration of inactive influenza virus in children. J. Clin. Invest. 26, 1079-1087 (1947).
11. Oh Y, Ohta K, Kuno-Sakai H, Kim D, Kimura M. Local and systemic influenza haemagglutinin-specific antibody responses following aerosol and subcutaneous administration of inactivated split influenza vaccine. Vaccine 10, 506-511 (1992).
12. Greenbaum E, Furst A, Kiderman A et al. Mucosal [SIGA] and serum [IgG] immunologic responses in the community after a single intra-nasal immunization with a new inactivated trivalent influenza vaccine. Vaccine 20, 1232-1239 (2002).
13. Samdal HH, Berstad AKH, Oftung F et al. An inactivated whole-virus influenza vaccine given intranasally induced protective levels of serum antibodies in humans. Proceedings of The Fourth Annual Conference on Vaccine Research, Arlington, VA, USA, April 2001, S33 (2001).
14. Haneberg B, Dalseg R, Wedege E et al. Intranasal administration of a meningococcal outer membrane vesicle vaccine induces persistent local mucosal antibodies and serum antibodies with strong bactericidal activity in humans. Infect. Immun. 66, 1334-1341 (1998).
15. Drabick JJ, Brandt BL, Moran EE, Saunders NB, Shoemaker DR, Zollinger WD. Safety and immunogenicity testing of nh intranasal group B meningococcal native outer membrane vesicle vaccine in healthy volunteers. Vaccine 18, 160-172 (2000).
16. Thomas G. Respiratory and humoral immune response to aerosol and intramuscular pertussis vaccine. J. Hyg. (Camb.) 74, 233-237 (1975).
17. Berstad AKH, Holst J, Frøholm LO et al. A nasal whole-cell pertussis vaccine induces specific systemic and cross-reactive mucosal antibody responses in human volunteers. J. Med. Microbiol. 49, 157-163 (2000).
18. Berstad AKH, Oftung F, Korsvold GE et al. Induction of antigen-specific T-cell responses in human volunteers after intranasal immunization with a whole-cell pertussis vaccine. Vaccine 18, 2323-2330 (2000).
19. Oftung F, Næss LM, Wetzler LM et al. Antigen-specific T-cell responses in humans after intranasal immunization with a meningococcal serogroup B outer membrane vesicle vaccine. Infect. Immun. 67, 921-927 (1999).
20. Hashigucci K, Ogawa H, Ishidate T et al. Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin. Vaccine 14, 113-119 (1996).
21. Glueck R. Review of intranasal influenza vaccine. Adv. Drug Delivery Rev. 51, 203-211 (2001).
22. Bourguignon P, Bisteau M, Abarca J et al. Reactogenicity in the nose and the brain of enterotoxins administered intranasally to mice. Proceedings of Molecular Approaches to Vaccine Design, Cold Spring Harbor, NY, USA, 1999, 23 (1999).
23. Ginkel FW van, Jackson RJ, Yuki Y, McGhee JR. Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J. Immunol. 165, 4778-4782 (2000).
24. Sun J-B, Holmgren J, Czerkinsky C. Cholera toxin B subunit: an efficient transmucosal carrier-delivery system for induction of peripheral immunological tolerance. Proc. Natl Acad. Sci. USA 91, 10795-10799 (1994).
25. Dalseg R, Holst J, Tangen T et al. Outer membrane vesicles from Group B meningococci can act as mucosal adjuvant for influenza virus antigens. In: Vaccines 96: Molecular Approaches to the Control of Infectious Diseases. Brown F, Norrby E, Burton D, Mekalanos J (Eds), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, USA, 177-182 (1996).
26. Berstad AKH, Andersen SR, Dalseg R et al. Inactivated meningococci and pertussis bacteria are immunogenic and act as mucosal adjuvants for a nasal inactivated influenza virus vaccine. Vaccine 18, 1910-1919 (2000).
27. Zollinger WD, Mandrell RE, McLeod Griffiss J. Enhancement of immunologic activity by noncovalent complexing of meningococcal group B polysaccharide and outer membrane proteins. In: Seminars in Infectious Disease (Vol. 4). Bacterial Vaccines. Robbins JB, Hill JC, Sadoff JC (Eds), Thieme-Stratton Inc., New York, NY, USA, 254-262 (1980).
28. Orr N, Robin G, Cohen D, Arnon R, Lowell GH. Immunogenicity and efficacy of oral or intranasal Shigella flexneri 2a and Shigella sonnei proteosome-lipopolysaccharide vaccines in animal models. Infect. Immun. 61, 2390-2395 (1993).
29. Fries LF, Montemarano AD, Mallett CP, Taylor DN, Hale TL, Lowell GH. Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults. Infect. Immun. 69, 4545-4553 (2001).
30. Haugan A, Wold N, Dao PXT et al. Bordetella pertussis may act as adjuvant as well as inhibitor of immune responses to nasal vaccines. Proceedings of The Fourth Annual Conference on Vaccine Research, Arlington, VA, USA, April 2001, S35 (2001).
31. Wu H-Y, Russell MW. Comparison of systemic and mucosal priming for mucosal immune responses to a bacterial protein antigen given with or coupled to cholera toxin (CT) B subunit and effects of pre-existing anti-CT immunity. Vaccine 12, 215-222 (1994).
32. Bergquist C, Lagergård T, Holmgren J. Anticarrier immunity suppresses the antibody response to polysaccharide antigens after intranasal immunization with the polysaccharide-protein conjugate. Infect. Immun. 65, 1579-1583 (1997).
33. Boyce TG, Hsu HH, Sannella EC et al. Safety and immunogenicity of adjuvanted and unadjuvanted subunit influenza vaccines administered intranasally to healthy adults. Vaccine 19, 217-226 (2001).
34. Hu K-F, Lövgren-Bengtsson K, Morein B. Immunostimulating completes (ISCOMs) for nasal vaccination. Adv. Drug Delivery Rev. 51, 149-159 (2001).
35. Jabbal-Gill I, Lin W, Kistner O, Davis SS, Illum L. Polymeric lamellar substrate particles for intranasal vaccination. Adv. Drug Delivery Rev. 51, 97-111 (2001).
36. McNeela EA, Mills KHG. Manipulating the immune system: humoral versus cell-mediated immunity. Adv. Drug Delivery Rev. 51, 43-54 (2001).
37. Singh M, Briones M, O'Hagan DT. A novel bioadhesive intranasal delivery system for inactivated influenza vaccines. J. Control Release 70, 267-276 (2001).
38. Bakke H, Setek TN, Haugen IL, Holst J, Aaberge IS, Haneberg B. The immunological memory and boosting of IgA antibodies in secretions induced by a nonreplicating nasal vaccine have different kinetics from those of IgG antibodies in serum. Proceedings of The Third Annual Conference on Vaccine Research, Washington DC, USA, April-May 2000, 63 (2000).
39. Illum L, Jabbal-Gill I, Hinchcliffe M, Fischer AN, Davis SS. Chitosan as a novel nasal delivery system for vaccines. Adv. Drug Delivery Rev. 51, 81-96 (2001).
40. Gizurarson S, Aggerbeck H, Gudbrandsson FK, Valdimarsson H, Heron I. Intranasal vaccination against diphtheria and tetanus in human subjects. Vaccine Res. 6, 41-47 (1997).
41. Aggerbeck H, Gizurarson S, Wantzin J, Heron I. Intranasal booster vaccination against diphtheria and tetanus in man. Vaccine 15, 307-316 (1997).
42. Katial RK, Brandt BL, Moran EE, Marks S, Agnello V, Zollinger WD. Immunogenicity and safety testing of group B intranasal meningococcal native outer membrane vesicle vaccine. Infect. Immun. 70, 702-707 (2002).
43. Fischer M, Holst J, Aaberge IS et al. Immunogenicity of an intranasal Neisseria meningitidis serogroup B outer membrane vesicle vaccine in adults. Proceedings of the Twelfth International Pathogenic Neisseria Conference, Galveston, Texas, USA, November 2000, 45 (2001).
44. Bakke H, Lie K, Haugen IL et al. Meningococcal outer membrane vesicle vaccine given intranasally can induce immunological memory and booster responses without evidence of tolerance. Infect. Immun. 69, 5010-5015 (2001).
45. Hvalbye BKR, Aaberge IS, Løvik M, Haneberg B. Intranasal immunization with heat-inactivated Streptococcus pneumoniae protects mice against systemic pneumococcal infection. Infect. Immun. 67, 4320-4325 (1999).
46. Janakova L, Bakke H, Haugen IL et al. Influence of intravenous anesthesia on mucosal and systemic antibody responses to nasal vaccines. Infect. Immunol. (In Press 2002).
47. Saunders NB, Shoemaker DR, Brandt BL, Moran EE, Larsen T, Zollinger WD. Immunogenicity of intranasally administered meningococcal outer membrane vesicles in mice. Infect. Immun. 67, 113-119 (1999).